Home  |  News  |  Sitemap  |  Contact Us  |  Login
Advertise With Us
Latest Notification
  • banner1
  • banner2
  • banner3
  • banner4
  • banner5
  • banner6
  • banner7
banner11 banner22 banner33 banner44 banner45 banner46 banner47

 Adverse Cases


Back Reported Adverse Drug Reaction Cases
Deaths with galantamine in mild cognitive impairment studies

Galantamine (Reminyl), donepezil (Aricept) and rivastigmine (Exelon) are approved in Australia for the treatment of mild to moderately severe Alzheimer's dementia. Cardiac arrhythmias with these cholinesterase inhibitors were described in the October 2004 Bulletin.1

Galantamine has also been investigated in patients with mild cognitive impairment, an indication which is not approved in Australia. In two placebo controlled trials (total of 2048 subjects), there was a higher mortality with galantamine (n=13) than placebo (n=1, relative risk 6.19, 95% confidence interval 2.17, 17.68), and galantamine was not effective.2 The deaths were due to various causes which could be expected in an elderly population.

A description of the results of these studies has recently been added to the 'Precautions' section of the Australian Product Information for Reminyl, along with further advice to use with caution in patients with cardiovascular and pulmonary conditions, particularly immediately after myocardial infarction and with new onset atrial fibrillation, second or third degree heart block, unstable angina and pneumonia.

ADRAC advises that galantamine should only be used for the approved indication of mild to moderately severe Alzheimer's dementia. The safety and efficacy in other indications have not been established and the risks may outweigh the benefit.

Reference
  1. ADRAC. Cholinesterase Inhibitors and Cardiac Arrhythmias. Australian Adverse Drug Reactions Bulletin, 2004; 23:5.
  2. http://www.clinicalstudyresults.org/drugdetails/? company_id=19&inn_name_id=66&indication_id=821&sort=c.company_name&page=1&drug_id=96
References:
Australian Adverse Drug Reactions Bulletin
Volume 25, Number 1, February 2006
domperidon milchbildung domperidon 60mg domperidon nebenwirkungen

Back


» Home
» Latest Notification
» New Drugs
» Import of Drugs
» Drug Prices
» Legislations
» Applications Forms
» Quackwatch
» Forms & Fees
» Licence Conditions
» Schedules
» Health, Pharma. Policies & Reports
» Ayurvedic
» Govt. Bodies
» Information Centre
» Directory
» Alert
» Regulatory News
» Research News
» News in Hindi
» Login
» Contact Us

Copyright © DrugsControl.org - Jaipur, INDIA. All Rights Reserved   |   Disclaimer   |   Sitemap

Site last updated: December 30, 1899 at